Journal of Shanghai Jiao Tong University (Medical Science) ›› 2023, Vol. 43 ›› Issue (2): 143-151.doi: 10.3969/j.issn.1674-8115.2023.02.002
• Basic research • Previous Articles
YI Xiaoxuan1(), HU Senlin2, SUN Yang2, HUANG Qingxia1(
), TANG Huiru1,3(
)
Received:
2022-12-08
Accepted:
2023-02-03
Online:
2023-02-28
Published:
2023-02-28
Contact:
HUANG Qingxia,TANG Huiru
E-mail:yixiaoxuanyxx@126.com;qingxhuang@fudan.edu.cn;huiru_tang@fudan.edu.cn
Supported by:
CLC Number:
YI Xiaoxuan, HU Senlin, SUN Yang, HUANG Qingxia, TANG Huiru. Quantitative characteristics of serum lipoprotein phenotypes for HBV patients[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(2): 143-151.
Characteristic | HBsAg (-) (n = 40) | HBsAg (+) (n = 35) | P value |
---|---|---|---|
Age/year | 57.75 ± 9.15 | 58.66 ± 9.08 | 0.669 |
Gender (male)/n(%) | 24 (60.00) | 22 (62.86) | 0.800 |
Hyperlipidemia/n(%) | 2 (5.00) | 3 (8.57) | 0.877 |
Hypertension/n (%) | 18 (45.00) | 18 (51.43) | 0.578 |
Diabetes/n(%) | 11 (27.50) | 13 (37.14) | 0.372 |
CHD/n(%) | 25 (62.50) | 26 (74.29) | 0.275 |
GPT/(U·L-1) | 22.20 ± 13.19 | 31.97 ± 34.24 | 0.310 |
GOT/(U·L-1) | 24.75 ± 19.94 | 33.31 ± 26.31 | |
hsCRP/(mg·L-1) | 8.52 ± 28.90 | 1.25 ± 2.92 | 0.735 |
HCY/(μmol·L-1) | 11.74 ± 6.27 | 13.24 ± 6.62 | 0.319 |
Creatinine/(μmol·L-1) | 75.23 ± 14.80 | 72.83 ± 16.86 | 0.514 |
UA/(μmol·L-1) | 329.69 ± 95.37 | 314.88 ± 97.70 | 0.509 |
Glucose/(mmol·L-1) | 6.71 ± 4.47 | 6.76 ± 3.63 | 0.729 |
CH/(mmol·L-1) | 4.14 ± 0.77 | 3.68 ± 0.90 | |
TAG/(mmol·L-1) | 1.70 ± 1.10 | 1.44 ± 0.76 | 0.339 |
HDL-Ch/(mmol·L-1) | 1.14 ± 0.22 | 1.09 ± 0.32 | 0.412 |
LDL-Ch/(mmol·L-1) | 2.41 ± 0.75 | 2.07 ± 0.57 |
Tab 1 Baseline characteristics of HBsAg (-) and HBsAg (+) populations
Characteristic | HBsAg (-) (n = 40) | HBsAg (+) (n = 35) | P value |
---|---|---|---|
Age/year | 57.75 ± 9.15 | 58.66 ± 9.08 | 0.669 |
Gender (male)/n(%) | 24 (60.00) | 22 (62.86) | 0.800 |
Hyperlipidemia/n(%) | 2 (5.00) | 3 (8.57) | 0.877 |
Hypertension/n (%) | 18 (45.00) | 18 (51.43) | 0.578 |
Diabetes/n(%) | 11 (27.50) | 13 (37.14) | 0.372 |
CHD/n(%) | 25 (62.50) | 26 (74.29) | 0.275 |
GPT/(U·L-1) | 22.20 ± 13.19 | 31.97 ± 34.24 | 0.310 |
GOT/(U·L-1) | 24.75 ± 19.94 | 33.31 ± 26.31 | |
hsCRP/(mg·L-1) | 8.52 ± 28.90 | 1.25 ± 2.92 | 0.735 |
HCY/(μmol·L-1) | 11.74 ± 6.27 | 13.24 ± 6.62 | 0.319 |
Creatinine/(μmol·L-1) | 75.23 ± 14.80 | 72.83 ± 16.86 | 0.514 |
UA/(μmol·L-1) | 329.69 ± 95.37 | 314.88 ± 97.70 | 0.509 |
Glucose/(mmol·L-1) | 6.71 ± 4.47 | 6.76 ± 3.63 | 0.729 |
CH/(mmol·L-1) | 4.14 ± 0.77 | 3.68 ± 0.90 | |
TAG/(mmol·L-1) | 1.70 ± 1.10 | 1.44 ± 0.76 | 0.339 |
HDL-Ch/(mmol·L-1) | 1.14 ± 0.22 | 1.09 ± 0.32 | 0.412 |
LDL-Ch/(mmol·L-1) | 2.41 ± 0.75 | 2.07 ± 0.57 |
1 | 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华肝脏病杂志, 2019, 27(12): 938-961. |
Chinese Society of Infectious Diseases Chinese Medical Association, Chinese Society of Hepatology Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B (2019 version)[J]. Chinese Journal of Hepatology, 2019, 27(12): 938-961. | |
2 | MCGLYNN K A, PETRICK J L, EL-SERAG H B. Epidemiology of hepatocellular carcinoma[J]. Hepatology, 2021, 73(S1): 4-13. |
3 | LIU Z Q, JIANG Y F, YUAN H B, et al. The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention[J]. J Hepatol, 2019, 70(4): 674-683. |
4 | NGUYEN M H, WONG G, GANE E, et al. Hepatitis B virus: Advances in prevention, diagnosis, and therapy[J]. Clin Microbiol Rev, 2020, 33(2): e0046-e0019. |
5 | BAR-YISHAY I, SHAUL Y, SHLOMAI A. Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression[J]. Liver Int, 2011, 31(3): 282-290. |
6 | HUANG Q X, LEI H H, DING L F, et al. Stimulated phospholipid synthesis is key for hepatitis B virus replications[J]. Sci Rep, 2019, 9(1): 12989. |
7 | JOO E J, CHANG Y, YEOM J S, et al. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study[J]. Hepatology, 2017, 65(3): 828-835. |
8 | WANG F B, ZHU C L, LIU X H, et al. HBV inhibits apoB production via the suppression of MTP expression[J]. Lipids Health Dis, 2011, 10: 207. |
9 | ZHU C L, GAO G S, SONG H, et al. Hepatitis B virus inhibits apolipoprotein A5 expression through its core gene[J]. Lipids Health Dis, 2016, 15(1): 178. |
10 | ZHU C L, ZHU H C, SONG H, et al. Hepatitis B virus inhibits the in vivo and in vitro synthesis and secretion of apolipoprotein C3[J]. Lipids Health Dis, 2017, 16(1): 213. |
11 | HSU C S, LIU C H, WANG C C, et al. Impact of hepatitis B virus infection on metabolic profiles and modifying factors[J]. J Viral Hepat, 2012, 19(2): E48-E57. |
12 | JAN C F, CHEN C J, CHIU Y H, et al. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening Study No. 10)[J]. Int J Obes (Lond), 2006, 30(5): 794-799. |
13 | QUAYE O, AMUZU B G, ADADEY S M, et al. Effect of hepatitis B virus (HBV) infection on lipid profile in Ghanaian patients[J]. Virology (Auckl), 2019, 10: 1178122X19827606. |
14 | TARGHER G, BERTOLINI L, PADOVANI R, et al. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C[J]. J Hepatol, 2007, 46(6): 1126-1132. |
15 | ZUO D, AN H H, LI J H, et al. The application value of lipoprotein particle numbers in the diagnosis of HBV-related hepatocellular carcinoma with BCLC stage 0-A[J]. J Pers Med, 2021, 11(11): 1143. |
16 | KULKARNI K R. Cholesterol profile measurement by vertical auto profile method[J]. Clin Lab Med, 2006, 26(4): 787-802. |
17 | RÁDIKOVÁ Ž, PENESOVÁ A, VLČEK M, et al. Lipoprotein profiling in early multiple sclerosis patients: effect of chronic inflammation?[J]. Lipids Health Dis, 2020, 19(1): 49. |
18 | KAUFMAN S L. Analysis of biomolecules using electrospray and nanoparticle methods: the gas-phase electrophoretic mobility molecular analyzer (GEMMA)[J]. J Aerosol Sci, 1998, 29(5/6): 537-552. |
19 | CLOUET-FORAISON N, GAIE-LEVREL F, GILLERY P, et al. Advanced lipoprotein testing for cardiovascular diseases risk assessment: a review of the novel approaches in lipoprotein profiling[J]. Clin Chem Lab Med, 2017, 55(10): 1453-1464. |
20 | JIMÉNEZ B, HOLMES E, HEUDE C, et al. Quantitative lipoprotein subclass and low molecular weight metabolite analysis in human serum and plasma by 1H NMR spectroscopy in a multilaboratory trial [J]. Anal Chem, 2018, 90(20): 11962-11971. |
21 | YASUMOTO J, KASAI H, YOSHIMURA K, et al. Hepatitis B virus prevents excessive viral production via reduction of cell death-inducing DFF45-like effectors [J]. J Gen Virol, 2017, 98(7): 1762-1773. |
22 | ZHANG J X, LING N, LEI Y, et al. Multifaceted interaction between hepatitis B virus infection and lipid metabolism in hepatocytes: A potential target of antiviral therapy for chronic hepatitis B [J]. Front Microbiol, 2021, 12: 636897. |
23 | ARAIN S Q, TALPUR F N, CHANNA N A, et al. Serum lipids as an indicator for the alteration of liver function in patients with hepatitis B[J]. Lipids Health Dis, 2018, 17(1): 36. |
24 | OEHLER N, VOLZ T, BHADRA O D, et al. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism[J]. Hepatology, 2014, 60(5): 1483-1493. |
25 | KONTUSH A, CHANTEPIE S, CHAPMAN M J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress[J]. Arterioscler Thromb Vasc Biol, 2003, 23(10): 1881-1888. |
26 | HAN Y H, ONUFER E J, HUANG L H, et al. Enterically derived high-density lipoprotein restrains liver injury through the portal vein[J]. Science, 2021, 373(6553): eabe6729. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 599
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 384
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||